Company Overview
BioMarin Pharmaceutical Inc. operates as a biotechnology company dedicated to the development and commercialization of therapies designed for life-threatening rare diseases and medical conditions across global regions including the United States, Europe, Latin America, the Middle East, and the Asia Pacific. The company functions within the healthcare sector, specifically inside the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at creating specialized treatments for underserved patient populations. This entity maintains a significant operational scale with a total market capitalization of $10.58B and reported annual revenue of $3.22B, supported by a workforce of 3221 employees. These valuation and revenue figures indicate that the company has established a substantial market position capable of sustaining extensive R&D operations and commercialization efforts while commanding a multi-billion dollar valuation relative to its sales base.
Financial Health
The company generated revenue of $3.22B over the trailing twelve months, resulting in a net income of $348.90M and an EBITDA of $722.89M, which reveals a cost structure where non-operating expenses and taxes consume a significant portion of earnings before interest and taxes. Free cash flow stands at $402.66M, indicating a robust generation of liquidity that provides the company with substantial financial flexibility to fund ongoing research projects or manage capital expenditures without relying heavily on external financing. Profitability analysis shows a gross margin of 52.8%, an operating margin of 22.5%, and a profit margin of 10.8%, suggesting that while production costs are managed efficiently, significant expenses related to R&D, sales, and administrative functions reduce the final profit relative to sales. The balance sheet reflects a conservative stance with total cash holdings of $1.56B exceeding total debt of $642.87M, further supported by a debt-to-equity ratio of 10.56% which suggests a low level of leverage relative to shareholders' equity. Liquidity is highly secure as evidenced by a current ratio of 5.21, meaning the company possesses more than five times the current assets needed to cover its short-term liabilities. Return on equity is measured at 5.9% and return on assets at 5.6%, metrics that reveal management effectiveness in generating returns from shareholder capital and total assets, respectively, though these percentages indicate moderate efficiency typical for capital-intensive biotechnology firms.
Valuation Assessment
Valuation metrics present a disparity between historical and future expectations, with a trailing P/E ratio of 30.57 compared to a forward P/E of 8.17, implying that the market anticipates a substantial expansion in earnings that will bring the multiple down to levels significantly lower than current historical performance. The price-to-book ratio is 1.74, indicating that the market values the company at a premium of 74% over its book value, which often reflects the intangible value of intellectual property and pipeline assets not captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 3.29 and an EV/EBITDA of 13.37, suggesting that investors are willing to pay a moderate multiple relative to sales and earnings power despite the high cost of capital inherent in the biotech sector. Price action over the last year shows a 52-week high of $73.18 and a 52-week low of $50.76, placing the current trading price within a range that reflects recent volatility but maintaining a position relative to these historical extremes. The stock exhibits a beta of 0.26, which signifies that the share price is less volatile than the broader market, moving with considerably lower sensitivity to general market fluctuations compared to large-cap technology or financial stocks.
Growth & Income
Revenue growth is recorded at 17.0% year-over-year, while earnings growth is listed as N/A, preventing a direct comparison of earnings velocity versus sales expansion but highlighting the focus on top-line expansion in the current period. Since the company does not pay a dividend, there is no dividend yield or payout ratio to assess for sustainability, meaning the firm retains all earnings to reinvest into growth initiatives, R&D pipelines, and strategic acquisitions rather than distributing cash to shareholders. This reinvestment strategy is characteristic of the biotechnology industry where capital allocation toward product development is prioritized over income generation for current holders. The overall growth and income profile is defined by strong revenue expansion without current income distribution, positioning the company as a pure growth vehicle dependent on the successful commercialization of its therapeutic portfolio to drive future value creation.